Abstract 25P
Background
Epithelial ovarian cancer (EOC) is a disease found mainly in advanced stages and difficult to treat. The study of the expression and methylation of miRNA genes can become the basis for the development of potential new diagnostic and prognostic markers of EOC, as well as the basis for the development of targeted anticancer therapy.
Methods
80 paired samples of EOC (ovarian serous adenocracinoma) were obtained from the National Medical Research Center of Oncology named after N.N. Blokhin. MicroRNA expression was assessed by TaqMan-qPCR with kits from Applied Biosystems, USA. Analysis of methylation of promoter CpG islands of microRNA genes was carried out using bisulfite conversion followed by methyl-specific PCR.
Results
The methylation frequency in the tumor was higher than in paired norm for 10 microRNA genes (MIR-124-1, -124-2, -124-3, -125B-1, -127, -129-2, -132, -137, -193A and -339; p ≤ 5×10-4). ROC analysis showed that a combination of 4 microRNA genes (MIR-124-2, -127, -129-2, -137) can be proposed as a panel of EOC detection markers with sensitivity (Sn) 80%, specificity (Sp) 82 %, AUC=0.86. The combination of miRNA genes (MIR-193A, -129-2, -137) was characterized by Sn=90%, Sp=75% and AUC=0.90. For 5 out of 12 microRNAs studied, a high frequency of reduced expression was observed: miR-125b-5p - in 59% of tumor samples compairing to paired norms, miR-129-5p - in 55%, miR-132-3p - in 55%, miR-137 - in 52% , and miR-193a-5p in 66% (p ≤ 0.05). The correlation of changes in the expression of 12 microRNAs (miR-124-3p, -125b-5p, -127-5p, 129-5p, -132-3p, -137, -148a-3p, -191-5p, -193a-5p, -203a, -339-3p and -375) and changes in methylation of the genes encoding them rs=0.67-0.97 (according to Spearman), p ≤ 10-4.
Conclusions
The role of methylation in the regulation of the expression of 12 microRNAs and the association of the methylation status of 10 microRNA genes with EOC metastasis were revealed. 5 microRNAs downregulated by hypermethylation may find use as potential targets for EOC therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The state task FGFU-2022-0007 of the Ministry of Science and Higher Education of the Russian Federation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
13P - Universal prospects of cryopreserved umbilical cord blood CD34+ progenitor cell-derived NK cells: Clinical and preclinical evaluation of non-engineered and genetically engineered candidates
Presenter: Anna-Maria Georgoudaki
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - Lentivirally overexpressed c-Myc promoter binding protein (MBP-1) localizes in the cytoplasm of human cutaneous melanoma cell lines increasing cell proliferation and glycolysis rate
Presenter: Miriam Hippner-Kunicka
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - Enhancement Platform for immune Cells (EPiC): invIOs’s innovative cell-therapy platform for creating personalized cancer treatments
Presenter: Mario Kuttke
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Melatonin modulates energy metabolism and kinases signaling in ovarian cancer cells
Presenter: Luiz Gustavo Chuffa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - New therapeutic target in triple-negative breast cancer for enhancing PARP inhibitor efficacy and stimulating the anti-tumour immune response
Presenter: Marina Rodriguez-Candela Mateos
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response
Presenter: Vlada Zakharova
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Presenter: Pranshu Sahgal
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Cross-resistance between platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi) in castration-resistant prostate cancer (CRPC)
Presenter: Peter Slootbeek
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage
Presenter: Wafaa Ramadan
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer
Presenter: Deniz Gulfem Ozturk
Session: Cocktail & Poster Display session
Resources:
Abstract